Co-Diagnostics/$CODX
1D1W1MYTD1Y5YMAX
Capital at risk
About Co-Diagnostics
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
- Ticker
- $CODX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 115
- Headquarters
- Salt Lake City, United States
- Website
- co-dx.com
Co-Diagnostics Metrics
BasicAdvanced
$6.8M
-
-$19.36
2.86
-
Price and volume
Market cap
$6.8M
Beta
2.86
52-week high
$13.54
52-week low
$0.91
Average daily volume
230K
Financial strength
Current ratio
1.813
Quick ratio
1.293
Long term debt to equity
0.08
Total debt to equity
0.142
Profitability
EBITDA (TTM)
-29.091
Gross margin (TTM)
43.48%
Net profit margin (TTM)
-6,523.05%
Operating margin (TTM)
-4,170.06%
Effective tax rate (TTM)
3.33%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-59.63%
Return on equity (TTM)
-174.77%
Valuation
Price to revenue (TTM)
3.639
Price to book
0.41
Price to tangible book (TTM)
0.96
Price to free cash flow (TTM)
-0.096
Free cash flow yield (TTM)
-1,046.46%
Free cash flow per share (TTM)
-11.301
Growth
Revenue change (TTM)
-28.12%
Earnings per share change (TTM)
-43.46%
3-year revenue growth (CAGR)
-53.76%
3-year earnings per share growth (CAGR)
-20.21%
Co-Diagnostics Financial Performance
Revenues and expenses
Co-Diagnostics Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.